论文信息 - Novel therapeutic targets in inflammatory bowel disease

Novel therapeutic targets in inflammatory bowel disease

SMAD7 antisense oligonucleotides and sphingosine‐1‐phosphate receptor modulators are new oral agents that are being investigated as potential treatments for inflammatory bowel disease (Crohn's disease and ulcerative colitis). This article reports on some of the clinical trial outcomes so far.

S. Chaplin

[1] G. Kaplan,et al. Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials , 2017, Alimentary pharmacology & therapeutics.

[2] S. Vermeire,et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.

[3] T. Macdonald,et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[4] B. Sands,et al. Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. , 2018, Gastroenterology.

[5] W. Sandborn,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.

[6] B. W. Kennedy. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease. , 2015, The New England journal of medicine.